Complexation of copper(II) 2,3,9,10,16,17,23,24-octahydroxy-29H,31H-phthalocyanine (CuPcOH) with copper(II) ions gives a two-dimensional (2D) metal-organic framework (MOF). This is the first report of a phthalocyanine-based MOF. This 2D MOF was obtained as a black powder and showed an electrical conductivity of 1.6×10 S cm at 80 °C. When this MOF is used as a cathode of lithium ion battery (LIB), large charge/discharge capacities of 151/128 mAh g were obtained. In addition, it showed a good stability during 200 charge/discharge cycles. The obtained LIB performance mainly originates from the electrically conductive and redox-active framework of the phthalocyanine-based 2D MOF and its hierarchical microporous/mesoporous structure.

MIL-101(Fe) was investigated as a cathode material of lithium ion batteries. A battery test reveals that MIL-101(Fe) shows a charge and discharge capacitance of 110 mA h g. It also showed reversible charge and discharge cycles and uptake of 0.62 Li/Fe after 100 cycles, which is the highest loading amount ever reported for the carboxylic MOFs. It also operates in the temperature range up to 350 °C and showed a good high thermal stability.

No abstract

We examined the effects of ornithine on the sleep-wake cycle by monitoring the electroencephalogram, electromyogram, and locomotor activity of freely moving mice after oral administration of it at lights-off time (18:00). Ornithine (1.0 and 3.0 g/kg of body weight) increased the amount of non-rapid eye movement (non-REM, NREM) sleep for 2 h after its administration, with a peak at 60 min post administration, to 164% and 198%, respectively, of that of the vehicle-administered mice, without changing the amount of REM sleep. The administration of ornithine at a lower dose (0.3 g/kg of body weight) did not increase the amount of NREM sleep compared with the vehicle administration. Ornithine did not affect the power spectrum density of NREM sleep but increased the number of episodes of wakefulness and NREM sleep and that of transitions between wakefulness and NREM sleep, and decreased the mean duration of wake episodes in a dose-dependent manner for 2 h after the oral administration. These results indicate that ornithine increased the amount of NREM sleep without reducing the power spectrum density of NREM sleep.

No abstract

No abstract

A retrospective study was conducted examining 25 patients with malignant melanoma who were treated by our new protocol for hyperthermic isolated limb perfusion. The characteristics of our techniques include: a lower priming volume of the extracorporeal circuit; a therapeutic temperature range of 40-41 degrees C with 60 min hyperthermic perfusion; a nominal perfusion flow rate of 500 ml/min in the lower limb and 200 ml/min in the upper limb; and combined carboplatin with interferon-beta as the adjuvant chemotherapy drug. In the lower extremity group, the arterial cannula size ranged from 8 to 14 F, while the venous cannula size ranged from 14 to 16 F. In the upper limb group, the arterial cannula size ranged from 6 to 8F and the venous cannula size ranged from 10 to 12F. No patient required any homologous blood transfusion postoperatively. No operative death or major complications occurred during the early postoperative period, confirming the safety of this treatment. Both optimal cannula size selection and maintaining perfusion temperature below 41 degrees C were judged to be important in elimination of vascular and deep tissue injury.

In this study, we investigated the antihypertensive effect of newly fermented SFS in SHRs. As a result of 13-wk SFS-administration, we found a significant antihypertensive effect of the SFS. This finding strongly demonstrates that the developed SFS would be greatly beneficial for health and useful for health-related industries.